Why the study?
Does the apolipoprotein E4 genotype increase the risk of vascular disease and atherosclerosis in patients with NIDDM and non-diabetic control subjects?
Population
206 subjects, comprising 83 patients with non-insulin-dependent diabetes mellitus and 123 control subjects.
Comparison
Apolipoprotein E4 (apo E4) genotype (E3/4, E4/4) vs Apolipoprotein E2/3 or E3/3 genotypes
Design
Cohort
Follow-up
10 years
Authors
Loading...
Apo E4 should not guide vascular risk assessment in NIDDM; leaves open its predictive value in non-diabetics.
Does the apolipoprotein E4 genotype increase the risk of vascular disease and atherosclerosis in patients with NIDDM and non-diabetic control subjects?
The apolipoprotein E4 genotype is a marker for increased vascular disease and atherosclerosis in non-diabetic individuals, but this effect is obscured by the overwhelming vascular risk conferred by Type 2 diabetes itself.
Vauhkonen et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: